Abel Hall LLC’s TG Therapeutics TGTX Stock Holding History

Abel Hall LLC’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$746K	Buy	13,570 +828	+6%	+$33.9K	0.13%	131
2026 Q1	$423K	Buy	+12,742	New	+$380K	0.09%	252

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Abel Hall LLC's TGTX Position: Q2 2026 in Review

Abel Hall LLC increased its TG Therapeutics (TGTX) stake by 6.5% in Q2 2026, buying an estimated $33.9K and bringing the position to 13,570 shares worth $746K. The position accounts for 0.13% of the portfolio, ranked #131.

Abel Hall LLC first reported a position in TGTX in Q1 2026 and has held it in 2 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Abel Hall LLC held 13,570 shares of TG Therapeutics worth $746K as of Q2 2026.
Abel Hall LLC bought 828 TG Therapeutics shares in Q2 2026, an estimated $33.9K.
TG Therapeutics made up 0.13% of Abel Hall LLC's portfolio in Q2 2026, its #131 holding.
Abel Hall LLC first reported a position in TG Therapeutics in Q1 2026 and has held it in 2 quarters since.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.